Risk factor screening scale to optimize treatment for potential heart transplant candidates under extracorporeal membrane oxygenation

Yih Sharng Chen, Wen Je Ko, Nai Hsin Chi, I. Hui Wu, Shu Chien Huang, Robert Jean Chen Chen, Nai Koun Chou, Ron Bin Hsu, Fang Yue Lin, Shoei Shen Wang, Shu Hsun Chu, Hsi Yu Yu

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We developed a risk factor-scaling score (RFSS) to select which patients supported by extracorporeal membrane oxygenation (ECMO) were suitable for ventricular assist device (VAD) implantation or heart transplantation (HTx). A total of 78 patients supported with ECMO for more than 48 h due to cardiac origin were included in this study. Patients were categorized into two groups based on the outcomes: the poor outcome group (n = 33) consisted of for those who later died or were later excluded from VAD or HTx; the favorable outcome group (n = 45) consisted of those who were weaned off ECMO finally and survived or were deemed suitable candidates for VAD or HTx. Seven risk factors were significant according to univariate analyses. Based on the regression coefficients of multivariate analysis, the RFSS was developed: (lung dysfunction × 7) + (systemic infection ×) + (peak lactate > 3 mmole/L × 3) + (kidney dysfunction × 2) + (creatine kinase > 10 000 U/L × 1). Patients with an RFSS of 7 or more were be allocated to the poor outcome group. The RFSS was validated by another group of 30 patients with good correlation. The RFSS provides a way to predict which ECMO-supported patients are suitable candidates for VAD implantation or HTx.

Original languageEnglish
Pages (from-to)1818-1825
Number of pages8
JournalAmerican Journal of Transplantation
Volume4
Issue number11
DOIs
Publication statusPublished - Nov 1 2004
Externally publishedYes

Fingerprint

Extracorporeal Membrane Oxygenation
Heart-Assist Devices
Transplants
Therapeutics
Heart Transplantation
Creatine Kinase
Lactic Acid
Multivariate Analysis
Kidney
Lung
Infection

Keywords

  • Extracorporeal membrane oxygenation
  • Heart failure
  • Risk factors
  • Transplantation
  • Ventricular assist device

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Risk factor screening scale to optimize treatment for potential heart transplant candidates under extracorporeal membrane oxygenation. / Chen, Yih Sharng; Ko, Wen Je; Chi, Nai Hsin; Wu, I. Hui; Huang, Shu Chien; Chen, Robert Jean Chen; Chou, Nai Koun; Hsu, Ron Bin; Lin, Fang Yue; Wang, Shoei Shen; Chu, Shu Hsun; Yu, Hsi Yu.

In: American Journal of Transplantation, Vol. 4, No. 11, 01.11.2004, p. 1818-1825.

Research output: Contribution to journalArticle

Chen, Yih Sharng ; Ko, Wen Je ; Chi, Nai Hsin ; Wu, I. Hui ; Huang, Shu Chien ; Chen, Robert Jean Chen ; Chou, Nai Koun ; Hsu, Ron Bin ; Lin, Fang Yue ; Wang, Shoei Shen ; Chu, Shu Hsun ; Yu, Hsi Yu. / Risk factor screening scale to optimize treatment for potential heart transplant candidates under extracorporeal membrane oxygenation. In: American Journal of Transplantation. 2004 ; Vol. 4, No. 11. pp. 1818-1825.
@article{3da57ecf9352446b847d6520eb0f2150,
title = "Risk factor screening scale to optimize treatment for potential heart transplant candidates under extracorporeal membrane oxygenation",
abstract = "We developed a risk factor-scaling score (RFSS) to select which patients supported by extracorporeal membrane oxygenation (ECMO) were suitable for ventricular assist device (VAD) implantation or heart transplantation (HTx). A total of 78 patients supported with ECMO for more than 48 h due to cardiac origin were included in this study. Patients were categorized into two groups based on the outcomes: the poor outcome group (n = 33) consisted of for those who later died or were later excluded from VAD or HTx; the favorable outcome group (n = 45) consisted of those who were weaned off ECMO finally and survived or were deemed suitable candidates for VAD or HTx. Seven risk factors were significant according to univariate analyses. Based on the regression coefficients of multivariate analysis, the RFSS was developed: (lung dysfunction × 7) + (systemic infection ×) + (peak lactate > 3 mmole/L × 3) + (kidney dysfunction × 2) + (creatine kinase > 10 000 U/L × 1). Patients with an RFSS of 7 or more were be allocated to the poor outcome group. The RFSS was validated by another group of 30 patients with good correlation. The RFSS provides a way to predict which ECMO-supported patients are suitable candidates for VAD implantation or HTx.",
keywords = "Extracorporeal membrane oxygenation, Heart failure, Risk factors, Transplantation, Ventricular assist device",
author = "Chen, {Yih Sharng} and Ko, {Wen Je} and Chi, {Nai Hsin} and Wu, {I. Hui} and Huang, {Shu Chien} and Chen, {Robert Jean Chen} and Chou, {Nai Koun} and Hsu, {Ron Bin} and Lin, {Fang Yue} and Wang, {Shoei Shen} and Chu, {Shu Hsun} and Yu, {Hsi Yu}",
year = "2004",
month = "11",
day = "1",
doi = "10.1111/j.1600-6143.2004.00578.x",
language = "English",
volume = "4",
pages = "1818--1825",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Risk factor screening scale to optimize treatment for potential heart transplant candidates under extracorporeal membrane oxygenation

AU - Chen, Yih Sharng

AU - Ko, Wen Je

AU - Chi, Nai Hsin

AU - Wu, I. Hui

AU - Huang, Shu Chien

AU - Chen, Robert Jean Chen

AU - Chou, Nai Koun

AU - Hsu, Ron Bin

AU - Lin, Fang Yue

AU - Wang, Shoei Shen

AU - Chu, Shu Hsun

AU - Yu, Hsi Yu

PY - 2004/11/1

Y1 - 2004/11/1

N2 - We developed a risk factor-scaling score (RFSS) to select which patients supported by extracorporeal membrane oxygenation (ECMO) were suitable for ventricular assist device (VAD) implantation or heart transplantation (HTx). A total of 78 patients supported with ECMO for more than 48 h due to cardiac origin were included in this study. Patients were categorized into two groups based on the outcomes: the poor outcome group (n = 33) consisted of for those who later died or were later excluded from VAD or HTx; the favorable outcome group (n = 45) consisted of those who were weaned off ECMO finally and survived or were deemed suitable candidates for VAD or HTx. Seven risk factors were significant according to univariate analyses. Based on the regression coefficients of multivariate analysis, the RFSS was developed: (lung dysfunction × 7) + (systemic infection ×) + (peak lactate > 3 mmole/L × 3) + (kidney dysfunction × 2) + (creatine kinase > 10 000 U/L × 1). Patients with an RFSS of 7 or more were be allocated to the poor outcome group. The RFSS was validated by another group of 30 patients with good correlation. The RFSS provides a way to predict which ECMO-supported patients are suitable candidates for VAD implantation or HTx.

AB - We developed a risk factor-scaling score (RFSS) to select which patients supported by extracorporeal membrane oxygenation (ECMO) were suitable for ventricular assist device (VAD) implantation or heart transplantation (HTx). A total of 78 patients supported with ECMO for more than 48 h due to cardiac origin were included in this study. Patients were categorized into two groups based on the outcomes: the poor outcome group (n = 33) consisted of for those who later died or were later excluded from VAD or HTx; the favorable outcome group (n = 45) consisted of those who were weaned off ECMO finally and survived or were deemed suitable candidates for VAD or HTx. Seven risk factors were significant according to univariate analyses. Based on the regression coefficients of multivariate analysis, the RFSS was developed: (lung dysfunction × 7) + (systemic infection ×) + (peak lactate > 3 mmole/L × 3) + (kidney dysfunction × 2) + (creatine kinase > 10 000 U/L × 1). Patients with an RFSS of 7 or more were be allocated to the poor outcome group. The RFSS was validated by another group of 30 patients with good correlation. The RFSS provides a way to predict which ECMO-supported patients are suitable candidates for VAD implantation or HTx.

KW - Extracorporeal membrane oxygenation

KW - Heart failure

KW - Risk factors

KW - Transplantation

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=7244221746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7244221746&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2004.00578.x

DO - 10.1111/j.1600-6143.2004.00578.x

M3 - Article

VL - 4

SP - 1818

EP - 1825

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 11

ER -